Compare Biogen Inc (BIIB) vs Monolithic Power Systems Inc (MPWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Monolithic Power Systems Inc — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Monolithic Power Systems Inc trades at $1,424 (market cap $68.90B). The key difference: Monolithic Power Systems Inc is far larger — about 2.3× Biogen Inc's market cap, and Monolithic Power Systems Inc pays a 0.57% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MPWR | |
|---|---|---|
Market Cap | $30.13B | $68.90B |
Sector | Health | Utilities |
52-Week High | $216.63 | $1.69K |
52-Week Low | $128.93 | $820.74 |
Enterprise Value | $37.20B | $67.51B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $206.48, down 0.31% on the day, with a bullish technical signal supported by moving averages. The company reported Q2 2026 EPS of $3.60, beating estimates of $2.94, and raised full-year guidance, driven by growth in Alzheimer's and rare disease portfolios. Recent acquisitions like RayThera and Apellis bolster its pipeline. Revenue for 2025 was $9.89 billion with a net income margin of 13.07%, though margins have fluctuated year-over-year.
Outlook remains positive with strong analyst support (62.5% buy rating) and a consensus price target of $234.47, implying ~14% upside. Key risks include reliance on new drug launches to offset declining multiple sclerosis sales and integration challenges from acquisitions. Cash flow trends show variability, with 2026 projecting negative net cash flow due to significant investing activities.
MPWR is trading at $1,437.94, up 4.12% today, reflecting strong momentum after recent earnings beats. The stock shows a bullish technical trend with support at $1,386 and resistance at $1,425. Fundamentally, Q2 2026 revenue surged to $980.6M, driven by 164.3% growth in Enterprise Data, with net income margin expanding to 24.5%. Analyst sentiment is overwhelmingly positive, with 88% recommending Buy and a consensus price target of $1,870.
Outlook remains favorable given robust AI-driven demand and upward earnings revisions, but risks include high valuation multiples (P/E 85.55) and potential double-ordering concerns. The stock offers growth exposure but requires monitoring of execution and competitive pressures in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Monolithic Power Systems Inc
Monolithic Power Systems, Inc. is a global leader in high-performance, analog, and mixed-signal semiconductors. The company specializes in power management solutions, providing integrated circuits (ICs) for a wide range of applications, including computing, automotive, industrial, and communications. MPWR's proprietary process technology is designed to deliver highly energy-efficient and compact power solutions, positioning the company as a key supplier for the next generation of electronic devices.
Read more on MPWR →
